Am J Psychiatry 155:1-2, January 1998
© 1998 American Psychiatric Association
ECT, Research, and Professional Ambivalence
Carl Salzman, M.D.
Modern psychiatry is becoming a data-based scientific discipline. As in other branches of medicine, diagnoses stem from increasingly rigorously defined criteria, and treatment recommendations are based on the results of controlled clinical trials. The days of "impressionistic," seat-of-the-pants formulations and treatments are rapidly disappearing.
Among psychiatric treatments, data for the efficacy of ECT, especially for the most severely depressed patients, are incontrovertible. Meta-analyses of ECT trials versus placebo, tricyclic or monoamine oxidase inhibitor antidepressants, or sham ECT convincingly demonstrate the efficacy of ECT (1). Use of modern anesthetic and ECT administration techniques has all but eliminated serious side effects. In addition, Olfson et al., in this issue of the Journal, have confirmed that ECT may lead to shorter and less costly inpatient care.
Given this demonstrated efficacy, safety, and economic savings, one would assume that the use of ECT would be more uniform throughout the United States. Hermann et al. (2), however, have demonstrated that use of ECT varies widely and depends on geographic location, with some areas of the United States hardly administering the treatment at all! It is likely that psychiatric residents in some residency training programs may never even see an ECT treatment, let alone administer a treatment and witness its efficacy.
If our psychiatric treatments are, indeed, based on the results of research, how, then, are we to account for the wide variability in ECT treatment in the United States? Despite the data, it appears that there continues to be ambivalence among American psychiatrists toward this efficacious and safe treatment. One reason may lie in its history of unmodified administration and the resultant side effects. Certainly films such as Shock Corridor, One Flew Over the Cuckoo's Nest, and Frances cannot have helped its reputation. However, there may be another more central reason for this ambivalence. With a few notable exceptions, there is little ECT research being conducted in major American psychiatric centers compared with research on pharmacological treatments. Many of the efficacy studies are one or more decades old. Rigorously designed multisite collaborative studies, using modern research techniques, of ECT's efficacy and predictors and correlates of response, relapse, and maintenance do not exist.
It appears that ECT has failed to attract current scientific curiosity. Despite a journal devoted exclusively to convulsive therapy, and a society of dedicated researchers and clinicians, there has not been the same systematic accretion of clinical research into ECT's mechanisms and efficacy as there has been for antidepressants. Examination of articles published in the past 3 years in The American Journal of Psychiatry, for example, reveals not a single controlled study of efficacy or mechanisms of action. Without such studies, there cannot be adequate comparison among modern psychiatric treatments, nor can knowledge increase regarding pathogenesis of psychiatric illness, as well as its treatment.
What is to be done? We lack comparisons of ECT's efficacy with adequately dosed trials of new antidepressants for all categories of depression, especially for our sickest patients. We need carefully collected data on the therapeutic impact of ECT for the suicidally depressed patient, both acutely and after treatment. Direct comparisons of long-term outcome, cost, and safety of ECT with pharmacological treatment are essential. In an effort to understand its therapeutic mechanisms, new research strategies such as imaging studies conducted before, during, and after ECT in depressed patients of all ages should be performed. Using modern molecular biology techniques, we need inquiry into acute and chronic effects of ECT on basic mechanisms of synaptic and second messenger function, neuronal adaptation, long-term plasticity, and hormonal response.
There is much fascinating research to conduct, if we can only overcome a professional ambivalence toward ECT and ignite the imagination and enthusiasm of our trainees and young research colleagues. Let us not perpetuate outmoded, nonscientific, and incorrect attitudes toward ECT in our younger colleagues. Rather, let us stimulate scientific curiosity and research into this cost-effective and safe psychiatric treatment.
FOOTNOTES
Address reprint requests to Dr. Salzman, Consolidated Department of Psychiatry, Harvard Medical School, Massachusetts Mental Health Center, 74 Fenwood Ave., Boston, MA 02115.
REFERENCES
-
Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr: Principles and Practice of Psychopharmacotherapy, 2nd ed. Baltimore, Williams & Wilkins, 1997, pp 373–374
-
Hermann RC, Dorwart RA, Hoover CW, Brody J: Variation in ECT use in the United States. Am J Psychiatry 1995; 152:869–875[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
L. M. Koran M.D.
Obsessive-Compulsive Disorder: An Update for the Clinician
Focus,
January 1, 2007;
5(3):
299 - 313.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Katon
Clinical practice. Panic disorder.
N. Engl. J. Med.,
June 1, 2006;
354(22):
2360 - 2367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Edlund and K. M. Harris
Perceived Effectiveness of Medications Among Mental Health Service Users With and Without Alcohol Dependence
Psychiatr Serv,
May 1, 2006;
57(5):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Goodwin and D. D. Montgomery
A Cognitive-Behavioral, Biofeedback-Assisted Relaxation Treatment for Panic Disorder With Agoraphobia
Clinical Case Studies,
April 1, 2006;
5(2):
112 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. A. FURUKAWA, N. WATANABE, and R. CHURCHILL
Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review
The British Journal of Psychiatry,
April 1, 2006;
188(4):
305 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. FRIEDLANDER, S. R. MARDER, E. C. SUNG, and J. S. CHILD
Panic disorder: Psychopathology, medical management and dental implications
J Am Dent Assoc,
June 1, 2004;
135(6):
771 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Bartels, A. R. Dums, T. E. Oxman, L. S. Schneider, P. A. Arean, G. S. Alexopoulos, and D. V. Jeste
Evidence-Based Practices in Geriatric Mental Health Care
Focus,
April 1, 2004;
2(2):
268 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Pollack, N. M. Simon, J. J. Worthington, A. L. Doyle, P. Peters, F. Toshkov, and M. W. Otto
Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder
J Psychopharmacol,
September 1, 2003;
17(3):
276 - 282.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. V. ERANTI and D. M. McLOUGHLIN
Electroconvulsive therapy -- state of the art
The British Journal of Psychiatry,
January 2, 2003;
182(1):
8 - 9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. N. Busch, B. L. Milrod, M. Rudden, T. Shapiro, J. Roiphe, M. Singer, and A. Aronson
How Treating Psychoanalysts Respond To Psychotherapy Research Constraints
J Am Psychoanal Assoc,
September 1, 2001;
49(3):
961 - 984.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. E. Watkins, A. Burnam, F.-Y. Kung, and S. Paddock
A National Survey of Care for Persons With Co-occurring Mental and Substance Use Disorders
Psychiatr Serv,
August 1, 2001;
52(8):
1062 - 1068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Mellman, A. L. Miller, E. M. Weissman, M. L. Crismon, S. M. Essock, and S. R. Marder
Evidence-Based Pharmacologic Treatment for People With Severe Mental Illness:A Focus on Guidelines and Algorithms
Psychiatr Serv,
May 1, 2001;
52(5):
619 - 625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Young, R. Klap, C. D. Sherbourne, and K. B. Wells
The Quality of Care for Depressive and Anxiety Disorders in the United States
Arch Gen Psychiatry,
January 1, 2001;
58(1):
55 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ende, D. F. Braus, S. Walter, W. Weber-Fahr, and F. A. Henn
The Hippocampus in Patients Treated With Electroconvulsive Therapy: A Proton Magnetic Resonance Spectroscopic Imaging Study
Arch Gen Psychiatry,
October 1, 2000;
57(10):
937 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Barlow, J. M. Gorman, M. K. Shear, and S. W. Woods
Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial
JAMA,
May 17, 2000;
283(19):
2529 - 2536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Andrews
Randomised controlled trials in psychiatry: important but poorly accepted
BMJ,
August 28, 1999;
319(7209):
562 - 564.
[Full Text]
|
|
|
|
|
|
|
M. V. RUDORFER and B. D. LEBOWITZ
Progress in ECT Research
Am J Psychiatry,
June 1, 1999;
156(6):
975 - 975.
[Full Text]
|
|
|
|
|
|
|
M. Z. Goldstein and K. Griswold
Practical Geriatrics: Cultural Sensitivity and Aging
Psychiatr Serv,
June 1, 1998;
49(6):
769 - 771.
[Full Text]
|
|
|
|
|
|
|
ECT for Recurrent Major Depression
Journal Watch Psychiatry,
March 1, 1998;
1998(301):
1 - 1.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
